The Europe BNP and NT-proBNP Market would witness market growth of 10.7% CAGR during the forecast period (2022-2028).
Cardiovascular (CVD) diseases, the leading cause of complications and mortality, need a thorough multi-parameter evaluation beyond the ECG. BNP and NTproBNP assays are essential for early monitoring, detecting, and treating cardiac issues. This enables more advanced and efficient cardiac care. The main behavioral risk factors for CVD, including heart disease and stroke, entail inadequate or incorrect dietary intake, inactivity, tobacco use, and excessive alcohol consumption.
In addition, behavioral risk factors in humans might manifest as high blood pressure, increased blood sugar, high blood lipids, being overweight, and obesity. These risk factors can be evaluated in the context of primary care and demonstrate a higher risk of consequences like heart attack, heart failure, and stroke.
The underlying factors of CVDs also include other factors. They illustrate the three key factors—urbanization, population aging, and globalization—that are bringing about transformation in economic, social, and cultural respects. Other CVD predictors include hereditary variables, stress, and poverty. Pharmacological treatment for high blood pressure or hypertension, diabetes, and high blood lipids is also necessary to reduce cardiovascular risk and prevent strokes as well as heart attacks in people with these disorders.
Every year, 3.9 million individuals in Europe die from cardiovascular disease. 37% of all mortality in the EU is caused by CVD. Central and Eastern Europe has more fatalities from IHD (ischemic heart disease) and stroke than other parts of Europe. Over 49 million people in the EU and 85 million in Europe are estimated to have cardiovascular disease in 2015. Of all the behavioral risk factors, food and eating habits had the greatest impact on the likelihood of CVD (cardiovascular disease) mortality and CVD DALYs (CVD disability-adjusted life years) at the population level in Europe. Similarly, the potential medical risk with the greatest effect is high systolic blood pressure. The demand for bnp and ntprobnp, propagating the expansion of the regional market.
The Germany market dominated the Europe BNP and NT-proBNP Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $147.4 Million by 2028. The UK market is anticipated to grow at a CAGR of 9.9% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 11.6% during (2022 - 2028).
Based on Location of Testing, the market is segmented into Point of Care Testing and Laboratory Testing. Based on Application, the market is segmented into Myocardial Infarction, Acute Coronary Syndrome (ACS), Congestive Heart Failure (CHF) and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide BNP and NT-proBNP Market is Projected to reach USD 2.2 Billion by 2028, at a CAGR of 11.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Siemens AG, Danaher Corporation, Gentian Diagnostics ASA, PerkinElmer, Inc., BioMérieux S.A., Quidel Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd. (Roche Holding Ltd.), and Scripps Laboratories.
Scope of the Study
Market Segments Covered in the Report:
By Location of Testing
- Point of Care Testing
- Laboratory Testing
By Application
- Myocardial Infarction
- Acute Coronary Syndrome (ACS)
- Congestive Heart Failure (CHF)
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Siemens AG
- Danaher Corporation
- Gentian Diagnostics ASA
- PerkinElmer, Inc.
- BioMérieux S.A.
- Quidel Corporation
- Bio-Rad Laboratories, Inc.
- F.Hoffmann-La Roche Ltd. (Roche Holding Ltd.)
- Scripps Laboratories
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe BNP and NT-proBNP Market, by Location of Testing
1.4.2 Europe BNP and NT-proBNP Market, by Application
1.4.3 Europe BNP and NT-proBNP Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe BNP and NT-proBNP Market by Location of Testing
3.1 Europe Point of Care Testing Market by Country
3.2 Europe Laboratory Testing Market by Country
Chapter 4. Europe BNP and NT-proBNP Market by Application
4.1 Europe Myocardial Infarction Market by Country
4.2 Europe Acute Coronary Syndrome (ACS) Market by Country
4.3 Europe Congestive Heart Failure (CHF) Market by Country
4.4 Europe Others Market by Country
Chapter 5. Europe BNP and NT-proBNP Market by Country
5.1 Germany BNP and NT-proBNP Market
5.1.1 Germany BNP and NT-proBNP Market by Location of Testing
5.1.2 Germany BNP and NT-proBNP Market by Application
5.2 UK BNP and NT-proBNP Market
5.2.1 UK BNP and NT-proBNP Market by Location of Testing
5.2.2 UK BNP and NT-proBNP Market by Application
5.3 France BNP and NT-proBNP Market
5.3.1 France BNP and NT-proBNP Market by Location of Testing
5.3.2 France BNP and NT-proBNP Market by Application
5.4 Russia BNP and NT-proBNP Market
5.4.1 Russia BNP and NT-proBNP Market by Location of Testing
5.4.2 Russia BNP and NT-proBNP Market by Application
5.5 Spain BNP and NT-proBNP Market
5.5.1 Spain BNP and NT-proBNP Market by Location of Testing
5.5.2 Spain BNP and NT-proBNP Market by Application
5.6 Italy BNP and NT-proBNP Market
5.6.1 Italy BNP and NT-proBNP Market by Location of Testing
5.6.2 Italy BNP and NT-proBNP Market by Application
5.7 Rest of Europe BNP and NT-proBNP Market
5.7.1 Rest of Europe BNP and NT-proBNP Market by Location of Testing
5.7.2 Rest of Europe BNP and NT-proBNP Market by Application
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 SWOT Analysis
6.2 Siemens AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 SWOT Analysis
6.3 Danaher Corporation
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Gentian Diagnostics ASA
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.5 PerkinElmer, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 BioMérieux S.A.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Quidel Corporation
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Bio-Rad laboratories, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expenses
6.9 F. Hoffmann-La Roche Ltd. (Roche Holding Ltd.)
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.10. Scripps Laboratories
6.10.1 Company Overview
TABLE 1 Europe BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 2 Europe BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 3 Europe BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 4 Europe BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 5 Europe Point of Care Testing Market by Country, 2018 - 2021, USD Million
TABLE 6 Europe Point of Care Testing Market by Country, 2022 - 2028, USD Million
TABLE 7 Europe Laboratory Testing Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Laboratory Testing Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 10 Europe BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 11 Europe Myocardial Infarction Market by Country, 2018 - 2021, USD Million
TABLE 12 Europe Myocardial Infarction Market by Country, 2022 - 2028, USD Million
TABLE 13 Europe Acute Coronary Syndrome (ACS) Market by Country, 2018 - 2021, USD Million
TABLE 14 Europe Acute Coronary Syndrome (ACS) Market by Country, 2022 - 2028, USD Million
TABLE 15 Europe Congestive Heart Failure (CHF) Market by Country, 2018 - 2021, USD Million
TABLE 16 Europe Congestive Heart Failure (CHF) Market by Country, 2022 - 2028, USD Million
TABLE 17 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 18 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 19 Europe BNP and NT-proBNP Market by Country, 2018 - 2021, USD Million
TABLE 20 Europe BNP and NT-proBNP Market by Country, 2022 - 2028, USD Million
TABLE 21 Germany BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 22 Germany BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 23 Germany BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 24 Germany BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 25 Germany BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 26 Germany BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 27 UK BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 28 UK BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 29 UK BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 30 UK BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 31 UK BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 32 UK BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 33 France BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 34 France BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 35 France BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 36 France BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 37 France BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 38 France BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 39 Russia BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 40 Russia BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 41 Russia BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 42 Russia BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 43 Russia BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 44 Russia BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 45 Spain BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 46 Spain BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 47 Spain BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 48 Spain BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 49 Spain BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 50 Spain BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 51 Italy BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 52 Italy BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 53 Italy BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 54 Italy BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 55 Italy BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 56 Italy BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 57 Rest of Europe BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 58 Rest of Europe BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 59 Rest of Europe BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 60 Rest of Europe BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 61 Rest of Europe BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 62 Rest of Europe BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 63 Key Information – Abbott Laboratories
TABLE 64 Key Information – Siemens AG
TABLE 65 Key Information – Danaher Corporation
TABLE 66 Key Information – Gentian Diagnostics ASA
TABLE 67 key Information – PerkinElmer, Inc.
TABLE 68 Key information – BioMérieux S.A.
TABLE 69 key information – Quidel Corporation
TABLE 70 Key Information – Bio-Rad Laboratories, Inc.
TABLE 71 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 72 Key Information – Scripps Laboratories
List of Figures
FIG 1 Methodology for the research
FIG 2 Swot analysis: Abbott laboratories
FIG 3 Swot analysis: Siemens AG